Clorox falls 3.5% as broader risk-off tape compounds lingering ERP and deal-leverage concerns

The Clorox Company (CLX) is down 3.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks driven primarily by a broad risk-off session that pressured defensive consumer names, with CLX also carrying stock-specific overhangs tied to its ERP transition and near-term earnings headwinds. Recent weakness has been amplified by investor sensitivity to leverage and execution risk as the company prepares to integrate a large acquisition.

Details:

U.S. equities sold off broadly amid renewed inflation worries linked to rising oil prices and escalating geopolitical tensions, lifting volatility and dragging most sectors lower.

CLX has been sliding over multiple sessions and recently underperformed large household and consumer peers during down-market days, suggesting momentum and positioning may be contributing.

In its Feb. 3, 2026 fiscal Q2 update, Clorox reaffirmed full-year guidance but highlighted that ERP-related shipment timing and retailer inventory drawdowns are expected to be a meaningful headwind to sales and EPS in fiscal 2026.

Clorox’s announced all-cash purchase of GOJO Industries (Purell) is expected to be largely debt-financed, which can weigh on sentiment when rates and risk premiums are moving higher.

Sources:

The Clorox Company, MarketWatch, Zacks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CLX Insider Trading Activity

$CLX insiders have traded $CLX stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $CLX stock by insiders over the last 6 months:

ERIC H REYNOLDS (EVP - Chief Operating Officer) sold 15,041 shares for an estimated $1,861,847
PIERRE R BREBER purchased 4,000 shares for an estimated $416,516

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CLX Hedge Fund Activity

We have seen 413 institutional investors add shares of $CLX stock to their portfolio, and 727 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,184,556 shares (-75.2%) from their portfolio in Q4 2025, for an estimated $321,098,781
STIFEL FINANCIAL CORP removed 2,378,720 shares (-78.3%) from their portfolio in Q4 2025, for an estimated $239,846,337
CITADEL ADVISORS LLC added 1,403,060 shares (+5350.3%) to their portfolio in Q4 2025, for an estimated $141,470,539
MORGAN STANLEY removed 902,664 shares (-28.2%) from their portfolio in Q4 2025, for an estimated $91,015,611
INVESCO LTD. added 884,751 shares (+22.1%) to their portfolio in Q4 2025, for an estimated $89,209,443
TWO SIGMA ADVISERS, LP removed 778,100 shares (-38.2%) from their portfolio in Q4 2025, for an estimated $78,455,823
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 739,005 shares (+6907.9%) to their portfolio in Q4 2025, for an estimated $74,513,874

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CLX Congressional Stock Trading

Members of Congress have traded $CLX stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $CLX stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 12/19 and 1 sale worth up to $15,000 on 11/12.
REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$CLX Analyst Ratings

Wall Street analysts have issued reports on $CLX in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Underweight" rating on 10/01/2025

To track analyst ratings and price targets for $CLX, check out Quiver Quantitative's $CLX forecast page.

$CLX Price Targets

Multiple analysts have issued price targets for $CLX recently. We have seen 10 analysts offer price targets for $CLX in the last 6 months, with a median target of $115.0.

Here are some recent targets:

Dara Mohsenian from Morgan Stanley set a target price of $136.0 on 02/05/2026
Javier Escalante from Evercore ISI Group set a target price of $115.0 on 02/04/2026
Peter Grom from UBS set a target price of $121.0 on 02/04/2026
Filippo Falorni from Citigroup set a target price of $115.0 on 02/04/2026
Andrea Teixeira from JP Morgan set a target price of $117.0 on 02/04/2026
Chris Carey from Wells Fargo set a target price of $115.0 on 01/23/2026
Robert Moskow from TD Cowen set a target price of $108.0 on 01/08/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.